Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry-Based Real-World Study
{{output}}
Background: Recent post-marketing studies have indicated a possible association between anti-CGRP receptor monoclonal antibodies (anti-CGRP-mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT). ... ...
